Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Ceftazidime-Avibactam Clear all
Completed Phase 1 Interventional Results available

Safety and Tolerability of Ceftazidime-Avibactam for Pediatric Patients With Suspected or Confirmed Infections

NCT01893346
View directory record Official record
Conditions
Systemic Infections
Interventions
CAZ-AVI
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
10
States / cities
Little Rock, Arkansas • Orange, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Steady-state Pharmacokinetics of Ceftazidime/Avibactam in Cystic Fibrosis

NCT02504827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ceftazidime/avibactam
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01595438
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
598 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sylmar, California • Royal Oak, Michigan • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Compared With Cefepime in Children From 3 Months to Less Than 18 Years of Age With Complicated Urinary Tract Infections (cUTIs)

NCT02497781
View directory record Official record
Conditions
Complicated Urinary Tract Infections
Interventions
Ceftazidime -avibactam, Cefepime
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
San Diego, California • Winston-Salem, North Carolina • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

NCT01290900
View directory record Official record
Conditions
Healthy Male Volunteers
Interventions
NXL104, Ceftaroline, Placebo Infusion, Ceftazidime, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Withdrawn Phase 4 Interventional

Imipenem/Cilastatin/Relebactam (IMI/REL) in Treatment of CRE Infections

NCT04785924
View directory record Official record
Conditions
Carbapenem-Resistant Enterobacteriaceae Infection, KPC, Gram-Negative Bacterial Infections, Antibiotic Resistant Infection
Interventions
Imipenem+Relebactam
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 3, 2024 · Synced Sep 4, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer

NCT02732327
View directory record Official record
Conditions
Neoplasms, Febrile Neutropenia
Interventions
CAZ-AVI, Vancomycin, Linezolid, Cefepime, Meropenem, Piperacillin/tazobactam
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Terminated Phase 2 Interventional Results available

Evaluation of Pharmacokinetics, Safety, and Tolerability of Ceftazidime-avibactam in Neonates and Infants.

NCT04126031
View directory record Official record
Conditions
Gram-negative Bacterial Infection
Interventions
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3, Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3
Drug
Lead sponsor
Pfizer
Industry
Eligibility
0 Days to 88 Days
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Boston, Massachusetts • Durham, North Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

NCT01534247
View directory record Official record
Conditions
Healthy
Interventions
CAZ-AVI, metronidazole, CAZ-AVI + metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Terminated Phase 4 Interventional Results available

Comparing Oral Versus Parenteral Antimicrobial Therapy

NCT05977868
View directory record Official record
Conditions
Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection, Gastrointestinal Infection, Genitourinary Infection
Interventions
Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections

NCT00752219
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
ceftazidime/NXL104 + metronidazole, meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Los Angeles, California • Palm Springs, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

NCT01499290
View directory record Official record
Conditions
Complicated Intra-Abdominal Infection
Interventions
CAZ-AVI, Metronidazole, Meropenem
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chula Vista, California • San Diego, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

NCT01599806
View directory record Official record
Conditions
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Doripenem, Either switch to oral therapy: 500 mg of Ciprofloxacin (oral), or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Detroit, Michigan • St Louis, Missouri • Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Not listed No phase listed Observational

Study of Ceftazidime-Avibactam Blood Concentrations in Intensive Care Unit Patients With Renal Failure Requiring Continuous Dialysis

NCT03243864
View directory record Official record
Conditions
Renal Failure, Bacterial Infections, Critical Illness
Interventions
Ceftazidime-avibactam
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602
View directory record Official record
Conditions
Healthy Male and Female Japanese Volunteers
Interventions
NXL104, CAZ104, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

NCT00690378
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
NXL104/ceftazidime, Imipenem/Cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam

NCT03978091
View directory record Official record
Conditions
Bacterial Infection
Interventions
AZACTAM, Ceftazidime-Avibactam
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

NCT02475733
View directory record Official record
Conditions
Complicated Intra-abdominal Infections
Interventions
Ceftazidime -avibactam, Meropenem, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Orange, California • San Diego, California • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Sep 4, 2026, 8:40 AM EDT
Completed No phase listed Observational Results available

Pharmacokinetics of Ceftazidime-avibactam Among Critically-ill Patients Receiving CVVHDF

NCT04358991
View directory record Official record
Conditions
Bacterial Infections
Interventions
Ceftazidime-avibactam
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2020 · Synced Sep 4, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

NCT01644643
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Complicated Intra-abdominal Infection
Interventions
Ceftazidime - Avibactam ( CAZ-AVI), Best Available Therapy, Metronidazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 90 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Shreveport, Louisiana • Lima, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2017 · Synced Sep 4, 2026, 8:40 AM EDT